Sopharma Trading AD (XBUL:SFT) Research & Development: €0 Mil (TTM As of Mar. 2026)


XBUL:SFT Sopharma Trading AD XBUL:SFT
80 GF Score
Price €3.00
GF Value €7.62
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Sopharma Trading AD Research & Development?

Sopharma Trading AD XBUL:SFT +2.74% 80 Research & Development is €0 Mil as of Mar. 2026. GuruFocus rates XBUL:SFT with a GF Score™ of 80/100 and a GF Value™ of €7.62 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sopharma Trading AD's Research & Development for the three months ended in Mar. 2026 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

Sopharma Trading AD  (XBUL:SFT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sopharma Trading AD Research & Development Related Terms

Sopharma Trading AD Research & Development Historical Data

* Premium members only.

The historical data trend for Sopharma Trading AD's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sopharma Trading AD Research & Development Chart

Sopharma Trading AD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sopharma Trading AD Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XBUL:SFT
80GF Score
Sopharma Trading AD XBUL:SFT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sopharma Trading AD Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
Sopharma Trading AD (XBUL:SFT) has a Research & Development of €0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Sopharma Trading AD and its competitors.
Is Sopharma Trading AD's Research & Development too high?
Sopharma Trading AD's current Research & Development is €0 Mil. Overall, Sopharma Trading AD has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's Research & Development compare to MCK and CAH?
Sopharma Trading AD's Research & Development of €0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sopharma Trading AD and its competitors. Sopharma Trading AD's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Based on GuruFocus' analysis, Sopharma Trading AD (XBUL:SFT) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.62, compared to a current price of €3.00 — trading 60.6% below its estimated fair value. The current Research & Development is €0 Mil. Sopharma Trading AD's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sopharma Trading AD (XBUL:SFT), the current Research & Development is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sopharma Trading AD (XBUL:SFT) Overvalued in 2026?

Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued. The current stock price of €3.00 is trading 60.6% below its estimated GF Value™ of €7.62. GuruFocus considers Sopharma Trading AD to be Significantly Undervalued.

Key valuation signals for XBUL:SFT:

  • Research & Development: €0 Mil
  • GF Value™: €7.62 vs. price of €3.00 (60.6% below fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the XBUL:SFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sopharma Trading AD Business Description

Address Sunrise Street, Lachezar Stanchev, 5 Sopharma, Business Towers, Building A Floor 12, Sofia, BGR, 1756
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
80GF Score

Get the complete analysis for XBUL:SFT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.00
Price
€7.62
GF Value